

AstraZeneca & 4baseCare enhance access to genomic testing for cancer patients in India

09 November 2022 | News

Strengthening the oncology ecosystem in the country thereby providing potential opportunities for improving long term outcomes significantly

Bengaluru-based precision oncology startup 4baseCare has announced a collaboration with AstraZeneca for advancing cancer care in India. Under this collaboration, the two organisations will support advanced-stage cancer patients with targeted therapy options using affordable genomic solutions.

AstraZeneca and 4baseCare will work with the oncologist community to support a large number of patients by providing services locally and also at a low cost ultimately increasing the chances of identifying optimal treatment options thereby improving clinical outcomes.

According to a report by the Indian Council of Medical Research (ICMR) on the 'Burden of cancers in India', seven cancers accounted for more than 40% of the total disease burden; lung and breast cancer being the highest. The number of Indians suffering from cancer is projected to increase to 29.8 million in 2025 from 26.7 million in 2021.

Given the advancement of technology in current times, patients have an opportunity to benefit significantly from various new age strategies including 'Precision Oncology'.

After doing massive research in collaboration with top hospitals and oncologists from India, 4baseCare recently launched a gene panel called TARGT IndieGene. It is India's largest and first population-specific tumour gene panel derived from Whole Exome and Whole Transcriptome data from over 1,500 cancer patients across 28 different cancer types.